Boston Scientific Expects to Miss Its 2026 Targets After a Cyberattack and Restores Cardiac Monitoring Signups
Boston Scientific announced it will likely miss its 2026 sales and earnings targets due to a cyberattack in late August. The attack disrupted order processing and prevented new patients from activating remote monitoring for cardiac devices. The company's shares fell over 4% to $45.73 on Tuesday. Boston Scientific expects to provide a revised outlook during its third-quarter earnings call on October 28, according to its SEC filing.
How this was made
The 30-second read
Why it matters
The guidance miss signals a material revenue shortfall and may prompt investors to reassess risk exposure to cyber incidents in the med‑tech sector.
Market read
Guidance miss and cyber‑risk highlight immediate downside for BSX and may influence sentiment across the broader med‑tech sector.
What to watch
Potential insurance recoveries or cost‑saving measures not yet disclosed.
Background
Boston Scientific suffered a cyberattack in late August that halted remote monitoring activations for new cardiac devices and disrupted order processing.
Ticker impact
Boston Scientific disclosed it will likely miss its Q3 and full‑year 2026 sales growth and adjusted EPS targets after a cyberattack, causing the stock to fall over 4% in Tuesday morning trading.
Downward pressure, likely 3‑5% further decline if guidance remains unchanged.
Guidance miss is a primary material event; shares already dropped 4% on the news, indicating immediate downside risk.
Market effects
Highlights cyber‑risk exposure for med‑tech firms; peers may see heightened scrutiny.
U.S. med‑tech sector could face short‑term volatility.
Limited to companies with similar supply‑chain dependencies.
Counterpoint
If the company recovers revenue faster than expected, the stock could rebound on the dip.
Key entities
- companyBoston Scientific
Medical device maker (ticker BSX) reporting missed 2026 targets.
- companyStryker
Peer mentioned as having faced similar cyber incidents.
- companyMedtronic
Peer mentioned in the article.
